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Abstract
Chikungunya virus (CHIKV), an alphavirus, has recently caused epidemic outbreaks and is therefore considered a re-
emerging pathogen for which no effective treatment is available. In this study, a CHIKV replicon containing the virus
replicase proteins together with puromycin acetyltransferase, EGFP and Renilla luciferase marker genes was constructed. The
replicon was transfected into BHK cells to yield a stable cell line. A non-cytopathic phenotype was achieved by a Pro718 to
Gly substitution and a five amino acid insertion within non-structural protein 2 (nsP2), obtained through selection for stable
growth. Characterization of the replicon cell line by Northern blotting analysis revealed reduced levels of viral RNA synthesis.
The CHIKV replicon cell line was validated for antiviral screening in 96-well format and used for a focused screen of 356
compounds (natural compounds and clinically approved drugs). The 5,7-dihydroxyflavones apigenin, chrysin, naringenin
and silybin were found to suppress activities of EGFP and Rluc marker genes expressed by the CHIKV replicon. In a
concomitant screen against Semliki Forest virus (SFV), their anti-alphaviral activity was confirmed and several additional
inhibitors of SFV with IC50 values between 0.4 and 24 mM were identified. Chlorpromazine and five other compounds with a
10H-phenothiazinyl structure were shown to inhibit SFV entry using a novel entry assay based on a temperature-sensitive
SFV mutant. These compounds also reduced SFV and Sindbis virus-induced cytopathic effect and inhibited SFV virion
production in virus yield experiments. Finally, antiviral effects of selected compounds were confirmed using infectious
CHIKV. In summary, the presented approach for discovering alphaviral inhibitors enabled us to identify potential lead
structures for the development of alphavirus entry and replication phase inhibitors as well as demonstrated the usefulness
of CHIKV replicon and SFV as biosafe surrogate models for anti-CHIKV screening.
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Introduction
Arthropod-borne viruses (arboviruses) are currently regarded as
re-emerging threats for health and well being in tropical regions
and, as a consequence of vector spread, also in more temperate
areas [1]. Factors including population growth and urbanization,
increased travel, ignorance of control methods for mosquito
vectors and climate change have been considered to contribute to
the increased risk of diseases caused by arboviruses, many of which
lack efficient antiviral therapies or vaccination [2].
Currently recognized arboviruses are single-stranded RNA
viruses in the families Flaviviridae, Togaviridae, Bunyaviridae and
Rhabdoviridae. Alphaviruses (within family Togaviridae) have envel-
oped virions of icosahedral symmetry and an RNA genome of
approximately 11.5 kb in size, which contains two open reading
frames [3]. These viruses enter their host cells via receptor-
mediated endocytosis. After fusion of the virus envelope with
endosomal membranes, the nucleocapsid is disassembled to release
the 59 capped positive stranded RNA genome. Immediate
translation of the RNA yields polyprotein P1234, the precursor
of virus nonstructural (ns) proteins nsP1-nsP4. Early processing of
the P1234 polyprotein releases the core polymerase subunit nsP4.
NsP4 together with the intermediate cleavage product P123 form
the negative strand RNA polymerase complex, producing the
templates for further positive strand synthesis. Processing of P123
results in the release of individual ns-proteins nsP1-nsP3, and
switches the RNA synthesis to production of RNA with positive
polarity. In addition to the genomic RNA coding for ns-proteins, a
subgenomic (sg) RNA is produced by internal initiation from the
negative strand template, allowing translation of virus structural
proteins. Nucleocapsids are assembled in the cytoplasm, and they
recognize the virus envelope proteins at the plasma membrane,
where budding occurs.
The clinical importance of alphaviruses has been underscored
by the recent epidemic outbreaks of Chikungunya virus (CHIKV)
in different sites around the Indian Ocean, including La Re ´union
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epidemic from 2005 to late 2007 has been estimated to include
more than 6 million cases. Furthermore, an outbreak of
approximately 200 confirmed cases took place in Italy, and
imported cases in travellers returning from endemic areas were
reported in several European countries, USA, Canada and
Australia [6], [7]. The ecology of arboviral species typically relies
on the amplification of viral pools in wild rodents or birds and
large outbreaks have been associated with nearby forest or wetland
to allow such zoonotic cycles [2]. However, the rise of mosquito
species adapted to urban environments (e.g. Aedes albopictus) has
changed the pattern, and the recent CHIKV epidemic is thought
to have arisen from direct human-to-human transmissions by
feeding mosquitoes [5].
Clinical CHIKV infection is characterized by acute, febrile
illness and high viremia (up to 10
10 copies/ml of viral genomes in
serum) that lasts for 3–10 days [8]. The clinical symptoms of
CHIKV and other Old World alphavirus infections include high
fever and other flu-like symptoms resulting from the proinflam-
matory cytokine response to virus, maculopapular rash and related
skin disorders, as well as gastrointestinal problems such as nausea
and vomiting. Approximately 10–30% of the patients suffer from
symptoms of connective tissues, mainly myopathy and arthralgia.
The joint pain resembles rheumatoid arthritis as it is most intense
in the small joints of extremities, and follow-up studies of patients
have indicated that these symptoms may persist for several months
[9]. The role of the proinflammatory response has been connected
also to the muscle and joint manifestations [10], and these
symptomatic tissues have also been shown to be the sites of in vivo
virus replication [11]–[13]. In the recent CHIKV outbreak, a high
proportion of neurological symptoms were observed in neonates
and small children infected with CHIKV [14]. Encephalitis and
meningoencephalitis were observed in half of the infected small
children, and persistent disabilities are estimated in 10–20% of
these cases.
The medical treatment of alphavirus infections relies on
symptomatic relief, as no effective treatment is available to affect
virus replication. During the 2006 La Re ´union outbreak, a double-
blind, randomized clinical trial was conducted to evaluate the
efficacy of chloroquine in acute CHIKV viremia, but the study
failed to show any benefits in terms of the duration of viremia or
the severity and duration of clinical symptoms [15]. Previous
reports on alphavirus inhibitors are scarce and involve mainly
broad-spectrum antiviral agents targeting cellular enzymes such as
inositol monophosphate dehydrogenase, S-adenosyl homocysteine
hydrolase and orotidine 59-phosphate decarboxylase [16]–[18].
Many of these compounds are limited by their narrow therapeutic
index or immunomodulatory effects that are considered unfavor-
able for the treatment of clinical infection.
The discovery of CHIKV inhibitors is hampered due to the
requirement for biosafety level 3 (BSL-3) handling. To overcome
this issue, we report in this study the generation of a stable BHK
cell line harboring non-cytotoxic CHIKV replicon and the
adaptation of this cell line as a screening tool for identification
of alphavirus inhibitors. A focused library of 123 natural and 233
pharmaceutical compounds was screened against the CHIKV
replicon, as well as against infectious Semliki Forest virus (SFV).
Activity of selected compounds was also confirmed using infectious
CHIKV. Furthermore, a virus entry inhibition assay was
established based on a temperature-sensitive (ts) SFV mutant
SFVts9. These experiments revealed the inhibition of CHIKV and
SFV replication by 5,7-dihydroxyflavones and the inhibitory effect
of 10H-phenothiazines on alphavirus entry. The approach used in
this study demonstrates the benefits and suitability of using
CHIKV replicon and SFV as biosafe surrogate models for anti-
CHIKV screening.
Results
Generation of a stable CHIKV replicon cell line
The most prominent human pathogen among the Old World
alphaviruses, CHIKV is an infectious agent that in most countries
requires handling in BSL-3 facilities. Our aim was to establish a
more screening-friendly assay system to identify inhibitors of
CHIKV replication (i.e., a BHK-based cell line containing
persistently replicating CHIKV replicon RNA). A selection
marker (puromycin acetyltransferase, Pac) and two reporter genes
(Renilla luciferase, Rluc and EGFP) were inserted into the sequence
of CHIKV-LR replicon originating from an isolate from La
Re ´union [19] (Fig. 1A). To reduce the cytotoxicity of the wild-type
CHIKV-LR replicon, a Pro718 to Gly substitution in nsP2,
previously shown to reduce the cytotoxicity of SFV and SINV
vectors [20]–[22], was introduced into the protease-encoding
section to yield CHIKV-PG. Without this mutation, all cells
transfected with transcripts from such vectors invariably died (data
not shown).
The selection process is illustrated in Fig. 1B. BHK cells
transfected with in vitro transcripts from the CHIKV-PG vector
were plated and puromycin selection (5 mg/ml) was applied starting
from 16 h post-transfection. Most of the cells died within four days,
but the remaining cells (roughly estimated as one out of 1610
5
transfected cells) expanded to cell clones which were transferred to
separate plates and subsequently expanded to cell lines under
continuous puromycin selection. The total RNA from 12
independent cell lines was purified and the regions corresponding
to CHIKV nsP2 were amplified by RT-PCR and sequenced to
identify mutations responsible for the non-cytotoxic phenotype of
the resulting replicon. Each of the identified mutations was
introduced into the CHIKV-PG vector and the BHK-21 cells,
transfected with such mutant replicons, were subjected to cell
viability assays (data not shown). Based on these experiments, a
single mutation representing an insertion of five amino acid residues
(GEEGS; sequence of the corresponding insert in the replicon RNA
was GGG GAG GAA GGG AGU) between residues 647 and 648
of CHIKV nsP2 was chosen. The insertion lay at a site where a
nuclear localization signal has been discovered in SFV nsP2 [23].
This mutation was incorporated into CHIKV-PG, together with an
Rluc marker fused with nsP3, to obtain CHIKV-NCT replicon
vector(Fig.1A).BHKcellstransfectedwiththis replicon wereviable
under continuous puromycin selection and were designated as
BHK-CHIKV-NCT cells.
Characterization of the BHK-CHIKV-NCT cell line
The appearance and speed of division of BHK-CHIKV-NCT
cells were similar to those of parental BHK cells, but these cells
were resistant to puromycin and expressed high levels of EGFP
(Fig. 1C) and Rluc markers throughout at least 20 passages. In
immunofluorescence studies, the BHK-CHIKV-NCT cells were
positive for double-stranded RNA (dsRNA) (Fig. 1D, top). The
cells could also be stained by polyclonal antibodies against SFV
nsP3 (Fig. 1D, middle), showing the cross-reactivity of these
antibodies with CHIKV nsP3. NsP3 and dsRNA were co-localized
in the replicon containing cells (Fig. 1D, bottom), indicating the
presence of replication complexes with a typical alphaviral
localization [24] in the perinuclear region of the cells and, in
minor quantities, at the plasma membrane.
To characterize the phenotypic changes caused by mutations in
the nsP2 region, the total RNA from BHK cells transfected with
Alphavirus Replication and Entry Inhibitors
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was analyzed using Northern blotting. This assay revealed that, in
contrast to SINV [21] and SFV [22], the introduction of the PG-
mutation into the CHIKV replicon led only to a slight reduction of
theaccumulationofreplicon andcorrespondingsgRNAs.However,
the levels of both replicon and sgRNAs of CHIKV-NCT were
severely reduced (Fig. 2A). At the same time the levels of marker
expression (both EGFP and Rluc) in CHIKV-NCT transfected cells
were comparable with those achieved by the use of CHIKV-LR or
CHIKV-PG replicons (before cell death occurred). The discrepancy
between the levels of viral RNAs and their translation products
could be explained by the lack of translational shutdown in the cells
transfected with CHIKV-NCT, which greatly enhances translation
of both genomic RNA and sgRNA, lacking the region correspond-
ing to the translational enhancer sequence of Sindbis virus (SINV).
A similar phenomenon has been previously described for related
SFV replicons [23], [25]. In addition, this analysis demonstrated
that the insertion of the Rluc marker into the nsP3 region had no
detectable effect on the replication and transcription of correspond-
ing replicons (Fig. 2A).
As the nuclear localization of nsP2 has been shown to affect the
cytotoxic properties of both SFV and replicons derived from it
Figure 1. Construction and characterization of a stable BHK cell line carrying CHIKV-replicon. A) Schematic representation of the used
CHIKV replicons (numbers and symbols are explained in the text). B) The process leading to selection of non-cytotoxic (NCT) CHIKV replicons,
identification of mutations associated with the NCT phenotype and confirmation of their phenotypes. C) Phenotype of BHK-CHIKV-NCT cells; green
fluorescence is caused by EGFP expression. Arrow indicates a cell in the process of division. D) Immunofluorescence images of BHK-CHIKV-NCT cells
stained with anti-dsRNA (top), anti-SFV nsP3 (middle) and co-staining with anti-dsRNA and anti-SFV nsP3 (bottom). A representative optical slice from
the middle of the cell is shown. Scale bar is 10 mm.
doi:10.1371/journal.pone.0028923.g001
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subcellular localization of nsP2 of CHIKV were analyzed by
immunofluorescence. This analysis revealed that at 8 h post-
transfection with CHIKV-LR RNA, a fraction of nsP2 was
localized in the nucleus of cells (Fig. 2B). Consistent with data
reported for SFV replicons, the presence of the PG-mutation
resulted in slightly increased nuclear localization of nsP2 (Fig. 2B),
while in cells transfected with CHIKV-NCT replicons, nsP2 was
largely, but not completely, excluded from the nuclei (Fig. 2B). It
should be noted that some variation in nsP2 localization between
individual transfected cells was also observed for each of the
analyzed constructs (data not shown).
The replicon present in BHK-CHIKV-NCT cells contains two
reporter genes, Rluc fused with CHIKV nsP3 and EGFP, which is
produced as a fusion protein with Pac under the sg-promoter
(Fig. 1A). EGFP is processed away from Pac by Foot-and-Mouth
Disease Virus (FMDV) 2A autoprotease sequence and is released
into the cytoplasm. The BHK-CHIKV-NCT cells had intense
luminescent and fluorescent signals when detected with a plate
reader in 96-well plate format, showing signal to background (S/B)
ratios of approximately 340 for the luminescent and approximately
60 for the fluorescent signal when the native BHK cells were used
as background.
For all experiments with antiviral compounds, puromycin was
excluded from the assay media to avoid puromycin-induced
toxicity as a response to suppression of Pac expression linked to the
replicon expression levels. The replicon responded to the reference
compounds used in the study in the low micromolar range. The
dose-response curves for ribavirin, mycophenolic acid and 6-
azauridine determined with both EGFP and Rluc signals revealed
sigmoidal, dose-dependent reduction in both marker levels. The
50% inhibitory concentrations (IC50) were approximately 1 mM
for mycophenolic acid and 6-azauridine with both reporter genes,
and 8.8 mM for ribavirin using EGFP and 25.4 mM using Rluc
(Table 1). Chloroquine showed no suppression of replicon
propagation, which was expected because of its mode of action.
It inhibits several viruses by blocking pH-dependent steps in virus
entry and maturation, neither of which are present in the used
replicon systems [26], [27]. Furthermore, the IC50 values of
ribavirin and mycophenolic acid were increased by at least two
orders of magnitude when the cultures were supplemented with
50 mg/ml guanosine (data not shown). This result indicated that
the observed suppression of EGFP and Rluc was a consequence of
cellular guanosine depletion, a generally accepted mode of action
for ribavirin and mycophenolic acid [28], [29].
Screening for CHIKV replication inhibitors
After characterization and adaptation for screening, the BHK-
CHIKV-NCT cell line was used for screening a total of 356
compounds, including 123 natural compounds and 233 clinically
approved drugs and other pharmaceutical compounds. These
libraries were selected due to the following reasons. First, natural
compounds, such as flavonoids and coumarins, are present in
herbal medicines typically used in the endemic areas of CHIKV
and therefore finding a potential inhibitor among these natural
compounds may provide evidence for the potential use of certain
herbal medicines to treat CHIKV infections. Second, by screening
a collection of known drugs instead of a random chemical library,
it is possible to focus the assaying on compounds that are already
shown to be clinically approved. After 48 h exposure of the
replicon-containing cell line to 50 mM compounds, EGFP levels of
the cell cultures were read as the endpoint for the primary screen.
The hit limit in the screen was set as .75% reduction of the EGFP
signal, and the antiviral activity of all compounds scoring as actives
was confirmed in a replicate experiment determining both EGFP
and Rluc marker levels. Dose-dependent suppression of the marker
genes included in the replicon vector after 48 h exposure was
observed for natural compounds apigenin, chrysin, naringenin and
silybin, and for one pharmaceutical compound, prothipendyl. The
IC50 values of the four natural compounds and prothipendyl are
presented in Table 1. As a measure of selectivity, the viability of
BHK-CHIKV-NCT cells after 48-h exposure with hit compound
concentrations of up to 200 mM was determined. As indicated in
Table 1, all compounds except naringenin (cell viability IC50
103.5 mM) and prothipendyl (cell viability IC50 185.6 mM) were
well tolerated by the BHK-CHIKV-NCT cells at the highest
concentration used (200 mM).
Screening against infectious SFV
Using a previously described antiviral assay based on an SFV
strain with Rluc inserted in between nsP3 and nsP4 (SFV-Rluc)
[30], the same set of 356 compounds was assayed against SFV, an
Figure 2. Effects of adaptive mutations on the CHIKV replicon.
A) Effects of the PG and NCT mutations on the accumulation of positive-
strand replicon and corresponding sgRNAs in cells transfected with in
vitro transcripts of CHIKV-LR, CHIKV-PG, CHIKV-NCT and their variants
containing the Rluc marker in the nsP3 region. Total RNAs extracted
from transfected cells at 16 h post-transfection; 10 mg aliquot from each
sample was separated by electrophoresis in formaldehyde gel and
analyzed by Northern blotting. The constructs are shown at the top;
positions of replicon and sgRNAs are indicated with arrows. ‘‘Mock’’
indicates RNAs from mock-transfected control cells. B) Immunofluores-
cence analysis of nsP2 localization in cells transfected with in vitro
transcripts of CHIKV-LR or CHIKV-PG at 8 h post-infection or with in vitro
transcripts of CHIKV-NCT at 16 h post-infection. Cells were fixed and
stained with anti-nsP2 and DAPI; EGFP was detected by fluorescence.
Merge indicates co-staining of DAPI and nsP2.
doi:10.1371/journal.pone.0028923.g002
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with SFV-Rluc (MOI 0.001), the compounds were added at 50 mM
concentration simultaneously with the virus inocula, and the
marker gene expression level was determined at 14 h post-
infection. Similarly to the CHIKV replicon screen, the hit limit of
.75% reduction of Rluc marker level was applied. After excluding
obviously toxic compounds (100% cell death detected by visual
inspection of non-infected cells under light microscope), 14 natural
compounds and 12 pharmaceutical compounds were identified as
screening hits against SFV-Rluc (Table 2). Consistent with the
CHIKV replicon screen, all five chemical agents identified as
CHIKV replicon inhibitors were found to inhibit SFV infection as
well. A complete list of primary screening results can be found in
Table S1.
The screening hits were further analyzed by dose-response
experiments. Cell viability IC50 values were determined as
described above and selectivity indices were calculated for each
compound as the ratio of cell viability and antiviral IC50. Table 2
presents antiviral and cell viability IC50 values, and selectivity
indices for all anti-SFV hit compounds. The results obtained with
positive controls mycophenolic acid, 6-azauridine, chloroquine
and 39-amino-39-deoxyadenosine are also included in Table 2.
Several anti-SFV screening hits exhibited antiviral IC50 values in
the low micromolar range. For example, a synthetic coumarin
derivative, coumarin 30, had an IC50 value of 0.4 mM against SFV
and a selectivity index of 308, whereas one of the flavonoids,
naringenin, had an IC50 value of 2.2 mM and a selectivity index of
47.
Inhibition of virus-induced CPE and SFV yield
A selectivity index .10 was set as a threshold for selecting anti-
SFV hit compounds for characterization by other assays, yielding
8 natural compounds and 7 pharmaceutical compounds. Con-
cerning these 15 selected compounds, studies were extended to
assay their capacity to reduce virus-induced cytopathic effect
(CPE) and to measure the inhibition of virus production. Besides
SFV, a distantly related member of the alphavirus genus, SINV,
was included in the CPE reduction studies as well. Table 3 lists the
IC50 values of these compounds in the CPE reduction assay for
both SFV and SINV, detected at 22 h and 24 h post-infection
(SFV and SINV, respectively; MOI 0.01) using WST-1 tetrazo-
lium salt to quantify cell viability. Although two natural
compounds and one pharmaceutical compound (protocatechuic
acid, pyrogallol and 17-ethinylestradiol) failed to inhibit the CPE
induced by SFV or SINV (determined with a cut-off value .25%
higher cell viability than in non-treated infection), all three
compounds showed reproducible inhibition in the primary
screening assay using SFV-Rluc. However, the lack of activity in
CPE reduction assay was consistent with the results from virus
production experiments, in which none of the three compounds
reduced SFV yields (see below). The remaining compounds
included in the experiments showed consistent results when
compared to the SFV-Rluc assay, exhibiting IC50 values in a
similar range as observed with the reporter gene assay. The
reference compounds ribavirin and mycophenolic acid performed
better in the CPE assay than in the screening assay: ribavirin had
an IC50 value of 28.1 mM against SFV and 51.8 mM against SINV
(compared to 95.1 mM in the screening assay). In the case of
mycophenolic acid, the values were 39.0 mM and 44.4 mM for
SFV and SINV in the CPE reduction, respectively, and 121.1 mM
in the reporter gene assay. Chloroquine, 39-amino-39-deoxyade-
nosine and 6-azauridine did not show similar shifts in IC50 values
between the two assays, resembling the newly identified antiviral
hit compounds in this respect.
The rightmost column in Table 3 lists the SFV yields in a virus
production assay, where BHK cells were infected with SFV (MOI
0.01) in the presence of 50 mM compounds. After 16 h, the
infection media were collected and SFV titers in each sample were
determined by plaque titration. Untreated control infection
yielded an SFV titer of 1.4610
9 PFU/ml under these conditions,
while ribavirin and mycophenolic acid decreased the virus titer by
approximately one order of magnitude, and chloroquine and 39-
amino-39-deoxyadenosine by two orders of magnitude. Among the
natural compound hits, apigenin and naringenin showed the
greatest decrease in SFV yield, both in the same range as reference
compounds used in the study (apigenin-treated infection yielded
an SFV titer of 6.7610
7 PFU/ml and naringenin-treated culture,
8.2610
7 PFU/ml). Among the pharmaceutical compounds, best
Table 1. Inhibition of CHIKV replicon in BHK-CHIKV-NCT cells by hit and reference compounds.
Compound EGFP
a IC50(mM) Rluc
aIC50(mM) Cell viability
b IC50 (mM)
NC compounds
Apigenin 22.5 28.3 .200
Chrysin 46.8 50.2 .200
Naringenin 25.8 30.0 122.1
Silybin 71.1 59.8 .200
PC compounds
Prothipendyl 135.0 93.3 185.6
Reference compounds
Ribavirin 8.8 25.4 .200
Mycophenolic acid 1.5 4.1 .200
6-Azauridine 2.4 3.1 .200
39-NH2-39-deoxyadenosine 34.0 62.4 187.1
aIC50 values for suppression of CHIKV replicon were determined by exposing the replicon cell line to test compounds at various concentrations from 200 mMt o1 0n M
for 48 h.
bCell viability IC50 values were determined by ATP assay after 48 h exposure of BHK-CHIKV-NCT cells. All results represent the mean values from two individual
experiments both run in triplicate (CV ranged from 4.9 to 13.7% in the CHIKV replicon assay). NC=natural compounds, PC=pharmaceutical compounds.
doi:10.1371/journal.pone.0028923.t001
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7 PFU/ml)
and opipramol (SFV titer 2.5610
8 PFU/ml).
SFV entry inhibition
Because the SFV screen revealed several hits not identified as
CHIKV replication inhibitors in the replicon assay, virus entry as
a potential target step for the anti-SFV activity was studied by
SFV-Rluc with a G389R point mutation in nsP2 (SFVts9-Rluc).
Based on our earlier work, this mutation causes defects in the
NTPase and RNA triphosphatase (RTPase) enzymatic activities of
the N-terminal domain of nsP2 and is accompanied by site-specific
defects in P1234 polyprotein processing [31], [32]. These defects
result in a ts-phenotype, characterized by severe defects in RNA
replication at an elevated temperature (0.5% of RNA replication
compared to wild-type SFV at 39uC), but replication levels are
comparable to the wild-type virus when grown at the permissive
temperature of 28uC. Because the virus is unable to multiply its
RNA genome at 39uC, all Rluc accumulating in BHK cells after
infection at the restrictive temperature results from the translation
of the initial RNA strands upon virus entry. This feature was used
to set up an assay to evaluate the effects of the hit compounds on
SFV entry by detecting Rluc in cell culture lysates infected with
SFVts9-Rluc at 39uC.
The ts-phenotype of the propagated SFVts9-Rluc virus was
confirmed in experiments performed at 39uC using wild-type SFV
as a control virus (Fig. 3A). At 28uC, the Rluc counts of SFVts9-
Table 2. Compounds that inhibit SFV replication in the SFV-Rluc screening assay.
Compound SFV
aIC 50 (mM) Cell viability
bIC50 (mM) SI
c
NC compounds
Alphanaphtoflavone 24.1 .200 .8.3
Apigenin 20.6 .200 .9.7
Bergapten 8.1 .200 .24.6
Chrysin 13.7 .200 .14.6
Coumarin 30 0.4 92.4 231
7-Diethylamino-3-thenoylcoumarin 5.1 39.1 7.7
4-Hydroxyacetophenone 21.1 164.0 7.8
Methyl umbelliferone 18.8 179.8 9.9
Naringenin 2.2 94.1 42.8
Propyl gallate 17.9 102.8 5.8
Protocatechuic acid 8.0 .200 .25.0
Pyrogallol 18.7 .200 .10.7
Quercitrin 23.7 .200 .8.4
Silybin 16.4 .200 .12.2
PC compounds
Chlorpromazine 15.7 67.3 4.5
Doxepin 14.5 .200 .13.8
Ethopropazine 16.0 166.9 10.4
17-Ethinylestradiol 9.5 .200 .21.1
Menadione 7.8 21.9 2.8
Methdilazine 11.3 63.8 5.6
Nadoxolol 16.4 .200 .12.2
Opipramol 19.7 .200 .10.2
Perphenazine 25.1 155.0 6.2
Prothipendyl 8.2 .200 .24.4
Thiethylperazine 15.0 83.1 5.5
Thioridazine 14.9 179.4 12.0
Reference compounds
6-Azauridine .200 .200 -
Chloroquine 13.4 .200 .14.9
39-NH2-39-deoxyadenosine 16.2 173.8 10.7
Mycophenolic acid 121.1 .200 .1.7
Ribavirin 95.1 .200 .2.1
aIC50 values for SFV replication were determined using SFV-Rluc infection (MOI 0.001 in BHK cells and detection at 14 h post-infection).
bCell viability IC50 values were determined by ATP assay after 48 h exposure of BHK cells.
cSelectivity indices (SI) were calculated as the ratio of the two values. All results represent the mean values of two individual experiments both run in triplicate (CV
ranged from 8.1 to 21.3% in the SFV-Rluc experiments). NC=natural compounds, PC=pharmaceutical compounds.
doi:10.1371/journal.pone.0028923.t002
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Chloroquine, a lysosomotrophic weak base with well-characterized
inhibitory effects on the entry of SFV and several other enveloped
viruses, was assayed in the system to define the sensitivity towards
chemical agents acting as entry inhibitors. The response to
chloroquine was measured at concentrations of 100 and 250 mM
and showed a dose-dependent inhibition of Rluc signal (Fig. 3B). At
lower concentrations of the drug, virus entry may slowly continue
at extended time points, leading to increases in the signal. Based
on this finding and the fact that without the drug, maximal signal
was reached in 1 h for SFVts9-Rluc (Fig. 3A), the 1-h end point
was selected for the library compound experiments.
To assay the hit compounds listed in Table 2 with the entry
inhibition assay, the compounds were added at 100 mM
concentration simultaneously with SFVts9 infection, and Rluc
activities were measured in lysates collected at 1 h post-infection.
Fig. 3C presents selected examples of the results with the hit
compounds. Six pharmaceutical compounds (chlorpromazine,
ethopropazine, methdilazine, perphenazine, thiethylphenazine
and thioridazine) decreased the Rluc activity, indicating that these
six compounds sharing a common core structure of 10H-
phenothiazine inhibited SFV entry. None of the other compounds,
including the flavonoids apigenin, chrysin, naringenin and silybin,
inhibited SFV entry in the assay.
Inhibitory activities of selected hit compounds against
infectious CHIKV
As demonstrated above, two surrogate models of CHIKV, the
BHK-CHIKV-NCT replicon cell line and related infectious SFV
can be used for screening of potential inhibitors. To validate the
selected hits, the recombinant CHIKV-LR virus with the Rluc
marker fused with nsP3 in the same way as in CHIKV-NCT
replicon (Fig. 1A), was constructed. The virus, designated as
CHIKV-Rluc, was found to be genetically stable and was used for
subsequent assays. In total, twelve compounds that were identified
in the screens described above were analyzed. These compounds
comprised five compounds originating from BHK-CHIKV-NCT-
based screens (Table 1), the most potent anti-SFV hit coumarin 30
and six SFV entry inhibitors (Fig. S1). 6-Azauridine was included
as a reference compound. The assay was carried out as described
for SFV-Rluc with modifications indicated in the Materials and
Methods section. Using this assay, 6-azauridine was found to
inhibit CHIKV-Rluc with an IC50 value 29.7 mM. This is slightly
higher than previously reported for CHIKV (0.2 mg/ml; approx-
imately 0.8 mM, ref. 16), which is in line with our earlier
observations that Rluc-based antiviral screening assays typically
yield slightly lower potency estimates than CPE or RNA labeling
assays. The IC50 value for 6-azauridine in the CHIKV-Rluc based
assay was approximately ten times higher than observed in the
Table 3. Inhibition of SFV and SINV replication by selected hit compounds measured by CPE reduction and virus production
assays.
Compound SFV
a IC50 (mM) SINV
a IC50 (mM) SFV yield
c (PFU/ml)
NC compounds
Apigenin 4.4 7.2 6.7610
7
Bergapten 9.2 16.2 1.2610
8
Chrysin 22.9 43.3 2.9610
8
Coumarin 30 5.5 11.8 5.0610
8
Naringenin 19.3 21.2 8.2610
7
Protocatechuic acid .200 .200 2.4610
9
Pyrogallol .200 .200 1.1610
9
Silybin 9.6 22.6 3.7610
8
PC compounds
Doxepin 50.7 41.1 3.6610
8
Ethopropazine 17.1 21.4 8.1610
8
17-Ethinylestradiol 63.0 56.8 9.0610
8
Nadoxolol 15.2 8.2 9.2610
7
Opipramol 25.0 31.0 2.5610
8
Prothipendyl 34.2 46.5 4.0610
8
Thioridazine 19.3 37.3 6.8610
8
Reference compounds
6-Azauridine .200 .200 9.1610
7
Chloroquine 8.2 11.3 3.3610
7
39-NH2-39-deoxyadenosine 17.5 23.4 2.7610
7
Mycophenolic acid 39.0 44.4 1.2610
8
Ribavirin 28.1 51.8 2.1610
8
aIC50 values against SFV and SINV were determined in dose-response experiments using an assay for the reduction of cytopathic effect. A concentration range from
200 mMt o0 . 1mM was applied for each compound. The results represent the mean values from two individual experiments, both run in triplicate (CV ranged from 9.9 to
18.6%).
cThe effect of hit compounds on SFV yield was analyzed by determining SFV titers of infection samples grown in the presence of 50 mM hit compound. The untreated
control sample had an SFV titer of 1.4610
9 PFU/ml. NC=natural compounds, PC=pharmaceutical compounds.
doi:10.1371/journal.pone.0028923.t003
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28923Figure 3. Virus entry assays with SFVts9-Rluc. A) The temperature-sensitive phenotype of SFVts9-Rluc as measured by Rluc activity of infected
cell lysates at 1 h, 2 h and 3 h post-infection at 39uC. B) The effect of chloroquine on Rluc signals of SFVts9-Rluc at 39uC. C) Effects of 5,7-
dihydroxyflavones and 10H-phenothiazines on the accumulation of Rluc in cells infected with SFVts9-Rluc at 39uC. Selected examples of results of hit
compounds in SFV entry inhibition assay. The cell cultures were treated with 100 mM compounds and Rluc levels were determined 1 h post-infection.
All results represent the average of three replicates.
doi:10.1371/journal.pone.0028923.g003
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observed for all of the other compounds tested. Aside from this
trend, the results obtained with CHIKV-Rluc were consistent with
those obtained using the surrogate systems. Similarly to the case of
SFV-Rluc (Table 2), coumarin 30 was found to be the most potent
inhibitor of CHIKV-Rluc as well (IC50 value of 6.4 mM). All
compounds that inhibited replication of CHIKV-NCT also
inhibited infection of CHIKV-Rluc:I C 50 of 70.8 mM for apigenin,
126.6 mM for chrysin, 118.4 mM for naringenin, 92.3 mM for
silybin and 97.3 mM for prothipendyl. Thus, apigenin was again
identified as the most potent inhibitor from this group of
compounds; however, the IC50 values for this compound and
the other compounds (except prothipendyl) were 2–3 fold higher
than those observed in the BHK-CHIKV-NCT cell-based assay.
All compounds identified as inhibitors of SFV entry also inhibited
CHIKV-Rluc infection. When compared to the SFV-Rluc based
screening results (Table 2), the entry inhibitors showed similar
potencies against the CHIKV-Rluc; however, the IC50 values
determined using the CHIKV-Rluc were higher (39.4 mM for
chlorpromazine, 48.1 mM for perphenazine, 61.5 mM for etho-
propazine, 63.8 mM for thietylperazine, 71.5 mM for thioridazine
and 84.5 mM for methdilazine) than the range of 11.3 mM–
25.1 mM. Thus, all compounds tested using infectious CHIKV
were confirmed to inhibit its infection, indicating that the use of a
combination of surrogate screening systems did not result in false-
positive hits.
Discussion
The current study presents the development of a novel tool for
bioactivity screening and molecular studies on CHIKV: a stable
BHK cell line harboring CHIKV replicon (BHK-CHIKV-NCT).
Phenotypic antiviral assays with infectious CHIKV cannot be
performed in most screening facilities due to BSL-3 requirements,
and thus far, only few studies have validated individual target
proteins as potential sites for medical intervention for CHIKV
[33]. Given the shortage in screening approaches with isolated
target proteins, CHIKV replicon cell lines offer a screening-
friendly approach in this respect. The BHK-CHIKV-NCT cell
line, persistently expressing a CHIKV replicon including Pac,
EGFP and Rluc, was found to grow as fast as the native BHK cell
line, to be stable for at least 20 passages, to express high levels of
both markers and to respond to known alphavirus replication
inhibitors in a concentration range comparable to previous
publications. The hits found using the BHK-CHIKV-NCT cell
line were confirmed by another novel tool, infectious CHIKV-
Rluc, indicating that the different nature of the screening system
and compromised replication of CHIKV-NCT replicon did not
result in selection of false-positive inhibitor candidates.
WithintheAlphavirusgenus, CHIKV and SFVbelong to thesame
antigenic serocomplex and are considered phylogenetically closely
related [34]. The well-conserved nature of the replicase proteins
within the two virus species was also demonstrated by the recog-
nition of CHIKV nsP3 by the anti-SFV nsP3 antibody. The high
level of correlation between the screening data with the two focused
libraries against the BHK-CHIKV-NCT replicon cell line and the
SFValsoprovidesproofthat SFVcanbeused asareliable surrogate
virusspecies fortheidentificationofbroad-spectrumantiviral agents
against CHIKVand otheralphaviruses.However,inthe case ofany
user-friendly surrogate system, the possibility of false-negative and
false-positive hits does exist. Therefore, the verification of the hits
using infectious CHIKV represents an important proof for the
applicability (and practical value) of these surrogate systems, as
shown in this study using infectious CHIKV-Rluc.
In vertebrate cells, wild-type alphaviruses cause an acute
infection characterized by CPE, a severe decrease in host cell
viability typically occurring within 24 h post-infection [35]. In the
case of Old World alphaviruses, CPE is induced at least in part by
nsP2, which is responsible for host cell transcriptional silencing via
an unidentified interaction of nsP2 with host cell factors, among
other actions [36], [37]. Thus, wild-type replicons of Old World
alphaviruses (e.g., SFV, SINV and CHIKV) cannot be used to
generate stable cell lines. Achieving this aim requires modification
of nsP2 to reduce the cytotoxicity of the replicon to the host cells.
These cell lines have been previously obtained for SINV and SFV
[25], [39] and used as tools for recombinant protein expression or
as tools for the study of protein function [25], [37]–[39]. However,
because these viruses do not represent significant human
pathogens, the use of these cell lines for antiviral drug development
has not been reported.
The requirements to achieve a non-cytotoxic phenotype of
replicons for different Old World alphaviruses are not identical. A
single point mutation [38], [39] or a five-amino acid insertion in
certain positions of nsP2 region [40] are both sufficient to create
non-cytotoxic SINV replicon and to obtain a stable BHK cell line
carrying such a replicon. In contrast to SINV, the P718G
(corresponding to P726G in SINV) or P718T mutation alone only
reduced the cytotoxicity of SFV replicons when applied individ-
ually but was not sufficient to make them non-cytotoxic [22], [25].
In the case of the SFV replicon with the P718T mutation, it was
shown that an additional R649H mutation, obtained during
puromycin selection, was required to achieve a truly non-cytotoxic
phenotype. Furthermore, it has been reported that the use of the
same selection procedure for CHIKV replicon with a P718S
mutation did not result in selection of any non-cytotoxic replicons
[41]. Because the approach successfully used in this study (Fig. 1B)
differed only in the mutation used in the original replicon (P718G
instead of P718S), one may speculate that the requirements for a
non-cytotoxic phenotype of CHIKV replicons are slightly different
and may be stricter than in the case of SFV. This assumption was
supported by the observation that the P718G mutation had only a
minor effect on RNA replication (Fig 2A) and cytotoxicity of
CHIKV replicons, while analogous the mutation in the SFV
replicon caused a much more prominent effect [22].
The reduction of replication/transcription is a common theme
for all non-cytotoxic replicons of Old World alphaviruses [21],
[22], [25], [38], and therefore, it is not surprising that the
CHIKV-NCT replicon clearly differed from the parental
CHIKV-LR replicon in reduced synthesis of viral positive-strand
RNAs (Fig. 2A). This finding is consistent with the data previously
reported for SFV vectors with reduced cytotoxicity [22] and
indicates that reduced replication is likely to represent one of the
factors contributing to the non-cytotoxic nature of CHIKV-NCT
replicons. In contrast, the significance of the nuclear location of
nsP2 for the non-cytotoxic phenotype is less clear [40]. The
PRRRV sequence, shown to function as a nuclear localization
signal in SFV nsP2 [23], is not well conserved within alphaviruses.
Additionally, for SINV nsP2, the nuclear transport of nsP2 does
not solely depend on the presence of SV40-type nuclear
localization signals [40]. In the region corresponding to the SFV
PRRRV sequence, the CHIKV nsP2 contains a PTKRV
sequence not predicted to represent a nuclear localization signal
(www.predictprotein.org). Interestingly, it is the very sequence that
was interrupted by a five amino acid insertion in CHIKV-NCT
(insertion occurred after Pro-residue), clearly indicating the
importance of this region for the phenotype of the CHIKV
replicon. However, it is not clear to what degree the nuclear
transport (or the lack of it) contributes to the non-cytotoxic
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that in cells transfected with the wild-type replicon (CHIKV-LR),
a significant amount of nsP2 was found in the nuclei. In contrast, a
lower degree of nuclear localization of nsP2 was generally
observed in cells transfected with CHIKV-NCT replicon
(Fig. 2B). The direct comparison of these phenotypes was,
however, not possible due to the different replication kinetics of
CHIKV-RL and CHIKV-NCT replicons (Fig. 2A) and the
cytotoxic properties of the former. Thus, the significance of this
phenomenon represents a topic of independent study beyond the
scope of this report.
The principal difference between the replicon and the infectious
virus screening assays used as primary screens is that in the case of
an infectious virus assay, chemical agents are allowed to interfere
with a system in which the virus is establishing its replicative
machinery after entering the host cell. However, in the replicon
cell-line based assay, the chemical agent is expected to suppress the
activity of already established replication complexes. Considering
the rapid onset of alphavirus infection, the need to suppress
established replication complexes may resemble more closely the
clinical situation, unless the medication is consumed as a
prophylactic agent. However, it has been demonstrated that the
non-cytopathic replicons of SFV and SINV differ from their wild-
type counterparts in that the replication complexes formed by
non-cytopathic replicons are unstable and are thus degraded and
rebuilt over time [37]. The recycling of the replication complexes
also leads to the presence of continuous negative strand RNA
synthesis in non-cytopathic replicons, which in the case of wild-
type virus is present only early in the infection before the stable
replication complexes have been established. In bioactivity
screening, the continuous negative strand synthesis may allow
the identification of chemical inhibitors also targeting this step in
virus replication. Indeed, four of five inhibitors of replication
discovered in this study were more potent against BHK-CHIKV-
NCT cells than against CHIKV-Rluc. However, as the same
tendency was also observed for other compounds, including entry
inhibitors, it is more likely that this trend was due to the lower
sensitivity of the CHIKV-Rluc based assay than systems used for
primary screens.
Another major difference between the two assays was that the
replicon system identifies only inhibitors targeting the replication
phase, whereas entry and maturation inhibitors can also be
identified in the SFV-Rluc infectious virus screen, the time course
of which encompasses 2–3 SFV replicative cycles in BHK cells.
This feature was also demonstrated by chloroquine used as a
reference compound in the study. This antimalarial agent inhibits
SFV in the infectious virus assay but has no effect on CHIKV
replicon, which is consistent with its well-documented mode of
anti-alphaviral action [26], [27]. Furthermore, the SFV-Rluc
screen identified several hits that did not suppress the CHIKV
replicon but were capable of inhibiting CHIKV-Rluc infection.
In the current study, new chemical agents with anti-alphaviral
properties were identified among both clinically approved drugs
and purified natural compounds. Many of the described
inhibitors showed similar or superior potency when compared
to previously published alphavirus inhibitors. For instance,
ribavirin and mycophenolic acid had IC50 values of roughly
100 mM in the screening assay, whereas several hit compounds
found had IC50 values between 10 and 20 mM. In the SFV yield
assay, positive controls reduced the virus titers by 1–2 orders of
magnitude, while the best hits of this study (apigenin, naringenin,
nadoxolol and opipramol) gave results in the same range. With
the standard compound 6-azauridine, we were also able to
confirm the previously reported differences in sensitivity between
alphaviral species towards this compound [16]. Although 6-
azauridine suppressed CHIKV replicon with IC50 values of
2.4 mM and 3.1 mM( EGFP and Rluc, respectively) and inhibited
CHIKV-Rluc (IC50 value 29.7 mM), it was able to inhibit SFV-
Rluc by only 40% at the highest concentration used (200 mM);
similar results were obtained in the CPE assay with both SFV and
SINV.
Natural compounds with a 5,7-dihydroxyflavone structure
(apigenin, chrysin, naringenin and silybin) inhibited CHIKV
replicon with IC50 values ranging from 22.5 mM to 71.1 mMi na
replicon cell line based assay and from 70.5 mM to 126.6 mMi na n
infectious CHIKV-Rluc based assay. Related flavonoids have been
reported to inhibit rhinovirus and picornavirus replication, and
flavonoids have also been widely studied against HIV [42], [43].
However, to our knowledge this is the first time that their activity
has been demonstrated against CHIKV or other alphaviruses.
Furthermore, although reports on inhibition of rhinoviruses,
picornaviruses and HIV suggest that flavonoids exert their
antiviral effects through entry inhibition, the four flavonoids
identified here suppressed CHIKV replicon levels with no effect
on SFV entry. These results indicate that their target site against
these viruses is replication rather than entry.
When the chemical structures of the identified inhibitors were
examined, 10H-phenothiazine core was identified in six out of
twelve pharmaceutical compound hits (Fig. S1). IC50 values
ranging from 11.3 mMt o2 5 . 1mM were determined for these
compounds against SFV-Rluc. When testing the compounds in
the SFVts9 entry assay, they were demonstrated to effectively
inhibit SFV entry into BHK cells, which was also consistent with
the fact that they did not have any effect on CHIKV replicon
expression levels but did inhibit the infection of CHIKV-Rluc.
Chlorpromazine, one of the six 10H-phenothiazines assayed, was
recently reported to also inhibit hepatitis C virus entry, and this
compound has been previously reported to inhibit clathrin-
mediated endocytosis by preventing the formation of clathrin-
coated pits at the plasma membrane [44]–[46]. Clathrin-
mediated endocytosis is the main route by which alphaviruses
and several other enveloped viruses enter their host cells. The
observed inhibition of SFV entry is likely the consequence of
misassembly of clathrin lattices in the presence of chlorproma-
zine. Besides chlorpromazine, we identified five other clinically
approved drugs sharing the same 10H-phenothiazine backbone
that also inhibited SFV entry. This finding suggests that
interference with clathrin-mediated endocytosis is a property
common for these closely related structures and that clathrin-
mediated endocytosis may be a viable target for novel entry
inhibitors against alphaviruses and other virus species relying on
this mechanism. Furthermore, many clinically approved drugs
carrying this structure are indicated for psychiatric or neurolog-
ical disorders, showing that this chemical scaffold may be a viable
starting point for identification of therapeutic agents capable of
crossing the blood-brain barrier. The relevance of this aspect in
the treatment of CHIKV is currently under debate. Although
recent studies have suggested that CHIKV is able to infect
neuronal cells and the 2005–2007 outbreaks were accompanied
with high numbers of pediatric CHIKV patients with neurolog-
ical symptoms, the animal models for CHIKV have shown no
positive immunostaining in the brains of the infected animals
[11], [13], [47], [48].
In conclusion, the current study presents the selection of a
stable BHK-based cell line harboring CHIKV non-cytotoxic
replicon and its successful use for inhibitor screening. Addition-
ally, evidence on the validity of SFV as a surrogate virus species
for screening of possible CHIKV inhibitors was demonstrated
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presented and by verification of selected hits using infectious
CHIKV-Rluc. A novel virus entry assay is presented using a ts-
mutant of SFV at elevated temperature. Inhibitors of alphavirus
replication showing two new lead structures, 10H-
phenothiazines and 5,7-dihydroxyflavones, were identified, the
former inhibiting virus entry and the latter preventing intracel-
lular replication.
Materials and Methods
Cells
Baby hamster kidney BHK21 cell line was purchased from the
American Type Culture Collection (ATCC CCL-10). The cells
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 8% fetal calf serum (FCS), 2% tryptose-broth
phosphate, 2 mM L-glutamine, 100 IU/ml penicillin and 100 mg/
ml streptomycin. The CHIKV replicon-containing BHK-
CHIKV-NCT cell line was maintained in the same medium
supplemented with 5 mg/ml puromycin.
CHIKV replicon cell line
A plasmid containing the cDNA of a CHIKV-La Re ´union (LR)
replicon that was used as starting material for the construction of
stable BHK cell lines harboring the non-cytotoxic (NCT) CHIKV
replicon was kindly provided by Dr. Stephen Higgs (University of
Texas Medical Branch, Galveston, TX, USA). This replicon is
based on the LR2006 OPY1 strain of CHIKV, which was
originally isolated from the serum of a febrile French patient
returning from La Re ´union Island [19]. A cassette encoding Pac
fused to EGFP via the 2A autoprotease element of FMDV was
inserted under the control of the sg-promoter of the CHIKV
replicon. Second, a mutation previously described to reduce the
cytotoxicity of the replicons of the related SFV [22] was
introduced into the nsP2 coding region (in the case of CHIKV
the change was P718 to G). The resulting mutant was designated
as CHIKV-PG. The mutation identified by sequencing of viral
RNA obtained from a cell clone stably harboring the CHIKV
replicon was introduced into CHIKV-PG by site-directed
mutagenesis (see Fig. 1A in the Results section). In addition, the
coding sequence of Rluc was inserted into the replicon vector after
the codon for amino acid 1823 of P1234 reading frame (after
codon 490 of nsP3). The resulting construct was designated
CHIKV-NCT and used for in vitro transcription and subsequent
transfection of BHK cells.
Confocal immunofluorescence microscopy was performed using
a Leica TCS SP5 confocal microscope with a HCX APO 636
glycerol objective, as described in [24]. A mouse monoclonal
antibody against dsRNA (J2) was purchased from Scicons
(Hungary). For the analysis of subcellular localization of wild-type
and mutant forms of nsP2, the BHK cells were transfected with in
vitro synthesized transcripts of CHIKV-LR, CHIKV-PG and
CHIKV-NCT replicons using the Lipofectamine 2000 reagent
(Invitrogen, USA), fixed at 8 h or at 16 h post-transfection and
stained with 49,6-diamidino-2-phenylindole (DAPI) and rabbit
polyclonal antibody against nsP2 of CHIKV (prepared in house).
For Northern blot analysis, 1610
6 BHK cells were transfected
with 50 mgo fin vitro transcribed RNA of CHIKV-LR, CHIKV-
PG or CHIKV-NCT replicons or that of their variants containing
the Rluc marker in the nsP3 region. At 16 h post-transfection, the
total RNA was isolated from the cells using Trizol reagent
(Invitrogen, USA) and analyzed as previously described [22] using
aP
32-labelled RNA probe complementary to the 39-UTR region
of CHIKV.
Viruses
Wild-type SFV and SINV stocks were derived from the
infectious clones pSFV4 and pTOTO1101 [49], [50] as described
in [30]. The working stocks were titrated, yielding titers of 4.5610
9
plaque forming units (PFU)/ml and 1.2610
9 PFU/ml for SFV
and SINV, respectively. SFV-Rluc, an SFV strain containing the
Rluc insertion, was produced from the infectious clone SFV-RlucH2
[30]. This stock was propagated similarly, yielding a working stock
with 1.5610
9 PFU/ml. SFVts9-Rluc virus, a ts-mutant with a
point mutation in nsP2 [31], [32], was modified to include Rluc in
a manner identical to SFV-Rluc. The virus stock was produced via
electroporation with the corresponding in vitro transcribed RNAs
into BHK cells. Plated cells were incubated at 28uC for 48 h. The
collected stock of SFVts9-Rluc was characterized for the ts-
phenotype.
The full-length infectious cDNA clone of CHIKV-LR2006
OPY1 was constructed from synthetic cDNA fragments (Geneart
AG, Germany) and fragments originating from cDNA clone of a
Mauritius isolate of CHIKV, kindly provided by Dr. Beate
Ku ¨mmerer (University of Bonn, Germany). The Rluc marker was
inserted into the region encoding nsP3 similar to the method used
for Rluc insertion into the CHIKV-NCT replicon. The resulting
clone was designated pCHIKV-Rluc. The virus was rescued from
in vitro produced transcripts in BHK-21 cells and checked for
genetic stability (indicated by the presence of the Rluc marker). The
working stock of CHIKV-Rluc was plaque-titrated in BHK cells,
yielding titers of 6.8610
7 PFU/ml. MEM supplemented with
0.2% bovine serum albumin (BSA) and 20 mM HEPES (pH 7.2)
was used as the medium for all infections.
CHIKV replicon screening assay
Before using the BHK-CHIKV-NCT cells for screening the
assay set-up was optimized and validated by testing different
conditions, such as seeding densities, incubation times and serum
concentrations (data not shown). In the optimized format with
EGFP detection, inter-plate and inter-day variations in the
normalized mid-signals were 4.7% and 7.4%, respectively. For
the screening, the cells were seeded onto opaque-white 96-well
plates with clear bottom at 3610
4 cells/well. The cells were
exposed to the test compounds after overnight incubation at
37uC. Compound stocks were diluted in DMEM supplemented
with 20 mM HEPES (pH 7.2), 5% FCS, 2 mM glutamine,
100 IU/ml penicillin and 100 mg/ml streptomycin. In a standard
assay, 48 h exposure was used prior to replicon expression
readout. Rluc expression was determined with a Renilla luciferase
assay kit (Promega, USA) according to the manufacturer’s
instructions (luminescence was recorded using 1 -s measurements
and automatic dynamic range setting). Before EGFP detection,
the cell cultures were washed with PBS and left with 100 mlo f
PBS for the measurement. The EGFP signal was read at 478/
508 nm (excitation/emission) using a 5 nm band width. Fluores-
cence and luminescence measurements were performed using a
Varioskan Flash plate reader (Thermo Fischer Scientific, Fin-
land).
SFV-Rluc and CHIKV-Rluc assays
A recently reported anti-alphaviral screening assay [29] was
used to determine inhibition of virus infection in cell cultures.
Briefly, confluent BHK cell cultures in 96-well plates were infected
with SFV-Rluc (MOI 0.001), and each library compound was
added into the wells simultaneously with the virus inoculum. At
14 h post-infection, the cultures were washed with phosphate-
buffered saline (PBS) and 20 ml of lysis reagent (Promega, USA)
was pipetted into the wells. The Rluc activity resulting from the
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lysates using a Renilla luciferase assay kit (Promega, USA) with a
Varioskan Flash plate reader as described above. For dose-
response experiments, a dilution series with concentrations of
0.01 mM, 0.1 mM, 1 mM, 5 mM, 10 mM, 25 mM, 50 mM, 100 mM
and 200 mM was used for each of the screening hits. Similar
conditions were used for confirmation of the hits in CHIKV-Rluc
assay except that Rluc activity was measured at 16 h post-infection
using a Glomax 96 microplate Luminometer (Promega, USA).
CPE reduction assay
CPE reduction was assayed using confluent BHK cell cultures in
96-well plates infected with either wild type SFV or SINV (MOI
0.01) in the presence of primary screen hits at various
concentrations. After optimizing the infection times (22 h for
SFV and 24 h for SINV), the cultures were washed twice with
Hank’s balanced salt solution and 10 ml of WST-1 Cell
proliferation assay reagent (Roche Diagnostics, Germany) was
added. After 1 h incubation, the absorbance at 440 nm was
measured to detect the presence of the reduced formazan product
using a Varioskan Flash plate reader.
Viral yield analysis using a plaque assay
BHK cells cultured on 35-mm dishes were infected with wild-
type SFV (MOI 0.01) in the presence of 50 mM hit compounds
and viruses were collected from the culture medium 16 h post-
infection. The viral yields from the collected medium samples were
titrated by infecting BHK cells on 6-well plates with serial dilutions
of each sample. After 1 h virus adsorption, the cultures were
washed and incubated for 48 h in MEM supplemented with 4%
FCS, 2 mM glutamine, 20 mM HEPES (pH 7.2), 100 IU/ml
penicillin and 100 mg/ml streptomycin and 0.45% carboxymethyl
cellulose. Afterwards, the cultures were washed with MEM + 0.2%
BSA and stained with crystal violet for quantification of plaques
produced by each dilution.
Entry inhibition assay
Confluent BHK cell cultures in 96-well plates were infected with
SFVts9-Rluc after equilibrating the cell cultures at 39uC. The
infected cultures were kept at 39uC until they were washed with
PBS, lysed and Rluc activities measured as described above.
Cell viability assay
BHK and BHK-CHIKV-NCT cells were seeded onto 96-well
plates at densities of 3610
4 cells/well, incubated overnight and
treated with the hit compounds at various concentrations. After
exposure for 48 h, cellular levels of ATP were determined as a
measure of cell viability after compound exposure [51]. Briefly,
plates were equilibrated to room temperature and 100 mlo f
CellTiter-GLOH luminescent cell proliferation assay reagent
(Promega, USA) was added. After 10 -min of shaking, the
luminometric readout was measured using a Varioskan Flash plate
reader as described above.
Compound libraries
Two compound libraries were included in this study: a
collection of 123 natural compounds, and a library of 233
pharmaceutical compounds. The natural compound library
consisted of commercially available pure natural products and
their synthetic derivatives, mainly flavonoids, coumarins and other
phenolic compounds. The collection of pharmaceutical com-
pounds contained clinically approved drugs in different therapy
areas as well as some metabolites of the drugs and other
pharmaceutical reagents. All compounds were obtained from
commercial sources (Table S1), dissolved in dimethyl sulfoxide
(DMSO) and stored as 20 mM stock solutions. The complete list of
compounds is presented in Table S1 along with the primary screen
data.
Reference compounds
Five previously published alphavirus inhibitors were used as
positive controls in this study. Ribavirin, mycophenolic acid,
chloroquine and 6-azauridine [16], [26], [42], [52] were
purchased from Sigma-Aldrich (USA), and 39-amino-39-deoxya-
denosine [30] was a gift from Prof. Seppo Lapinjoki (University of
Kuopio, Finland). These compounds were also dissolved in
DMSO and stored as 20 mM stocks.
Data analysis
All data from the antiviral and cell viability assays were
normalized using untreated infections and noninfected cell
cultures (in antiviral assays) or nontreated and reagent background
samples (in cell viability assays), which were set as 100% and 0%
values, respectively. Antiviral and cell viability IC50 values were
determined by fitting the results from dose-response studies into
sigmoidal dose-response curves with GraphPad Prism 5.0
software.
Supporting Information
Figure S1 Chemical structures of 10H-phenothiazines identified
as SFV entry inhibitors.
(DOCX)
Table S1 Primary screening of chemical libraries. Compounds
were tested at 50 mM concentration. See Materials and Methods
of the article for experimental details.
(XLS)
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